title: Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
abstract: OBJECTIVE
  To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia (ALL).
  
  
  METHODS
  Fifty-eight patients were randomly assigned to etoposide at 50 mg/m(2)/d with once- versus twice-daily doses for 22 days. On day 8, vincristine, asparaginase, and dexamethasone were started. Etoposide pharmacokinetics and pharmacodynamics were studied for 47, 28, and 26 patients on day 1, 8, and 22, respectively, of remission reinduction therapy.
  
  
  RESULTS
  Of 48 patients with pharmacokinetic data, 42 (87.5%) achieved complete remission, three (6.3%) failed to achieve remission, and three (6.3%) died during induction. Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively). Three of eight patients with plasma concentrations exceeding 1.7 micro M (1 micro g/mL) for more than 8 hours daily, compared with one of 20 patients with concentrations exceeding 1.7 micro M for <or= 8 hours daily, were unable to receive all 22 days of etoposide because of toxicity. There was no difference in the AUC at day 1 or day 8 with once- versus twice-daily doses (P =.55 and P =.86, respectively).
  
  
  CONCLUSIONS
  A pharmacodynamic relationship exists between systemic etoposide exposure and response to therapy when oral etoposide is used as part of remission induction regimens for relapsed or refractory childhood ALL.
authors.affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, and College of Pharmacy, The University of Tennessee, Memphis 38105, USA.
authors.forename: Mathew J
authors.initials: MJ
authors.lastname: Edick
authors.forename: Amar
authors.initials: A
authors.lastname: Gajjar
authors.forename: Hazem H
authors.initials: HH
authors.lastname: Mahmoud
authors.forename: Matthijs E C
authors.initials: ME
authors.lastname: van de Poll
authors.forename: Patricia L
authors.initials: PL
authors.lastname: Harrison
authors.forename: John C
authors.initials: JC
authors.lastname: Panetta
authors.forename: Gaston K
authors.initials: GK
authors.lastname: Rivera
authors.forename: Raul C
authors.initials: RC
authors.lastname: Ribeiro
authors.forename: John T
authors.initials: JT
authors.lastname: Sandlund
authors.forename: James M
authors.initials: JM
authors.lastname: Boyett
authors.forename: Ching-Hon
authors.initials: CH
authors.lastname: Pui
authors.forename: Mary V
authors.initials: MV
authors.lastname: Relling
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D019540:Area Under Curve; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003907:Dexamethasone / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D001215:Asparaginase